Dr Stephen Bright is a clinically trained psychologist and senior lecturer on addiction at Edith Cowan University. Dr. Bright is the director of PRISM, the Psychedelic Research in Science and Medicine organisation which is a not for profit, independent research charity developing medical and legal processes for the application of psychedelic medicines for improved well being in Australia.
In this conversation Dr. Stephen shares an update on the research for MDMA and psylicybin in the US and Australia, some of the results of the studies, the reactions from the clinical community, regulators and the public as well as Dr. Bright’s view on how psychedelic assisted therapy will come to play a role in clinical practice.
Some websites we discussed:
https://clinicaltrials.gov/ is the platform to find out which studies are running
https://www.prism.org.au/prismsresearch/ is a summary of research and PRISM’s website
You can connect with Dr. Bright here: s.bright@ecu.edu.au
The drug-harm chart by Prof David Nutt has been summarised well here:
https://www.businessinsider.com/chart-drugs-that-cause-the-most-harm-2013-9
The original paper from Prof David Nutt was published in the Lancet and can be found here:
https://www.researchgate.net/publication/47635105_Nutt_DJ_King_LA_Phillips_LD_Drug_harms_in_the_UK_a_multicriteria_decision_analysis_Lancet_376_1558-1565
Create your
podcast in
minutes
It is Free